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Conclusion: Performance analysis of a set of standardized cognitive
tasks indicates almost all practicing senior surgeons perform at or near the
level of younger colleagues, as do almost half of retired senior surgeons.
Summary: Nearly 20% of practicing physicians are aged 65 and
20% of adults aged 70 have some form of cognitive impairment (Plass-
man BL et al, Ann Intern Med 2008;144:427-34). Therefore, there is
interest in detection of cognitive deficits to reduce the prevalence of aging
physicians with cognitive impairment. The authors have previously shown
that measures of cognitive skill, including attention, reaction time, visual
learning, and memory, decline with age among surgeons but that subjective
evaluation of cognitive decline does not reflect objective measures of cogni-
tive status. In this study, as part of the Cognitive Changes in Retirement
Among Senior Surgeon Study, the authors examined objective cognitive
function of senior surgeons with respect to retirement status and age. The
authors administered computerized cognitive tasks that assessed reaction
time, visual sustained attention, memory, and visual learning to practicing
and retired surgeons at annual meetings of the American College of Sur-
geons. There were 168 senior surgeons aged60 years who were compared
with 126 younger surgeons aged 45 to 59 years. Performance below 1.5
standard deviations was felt to indicate a significant difference between
groups.
Sixty-one percent of practicing senior surgeons performed within the
range of the younger surgeons on all cognitive tasks, and 78% of practicing
senior surgeons aged 60 to 64 years performed within the range of younger
surgeons on all tasks. This was compared with 38% of practicing senior
surgeons aged 70 years. Among retired senior surgeons, 45% performed
within the range of younger surgeons on all tasks. No senior surgeons
performed below younger surgeons on all three tasks. The task of visual
learning andmemory was most difficult for senior surgeons, where one-third
performed below younger surgeons. However, only 3 of 168 senior sur-
geons performed below younger surgeons on measures of reaction time,
indicating less effect on psychomotor speed by age in this group. Only 7 of
108 practicing senior surgeons performed significantly below younger sur-
geons on more than one task.
Comment: The data indicate most senior surgeons perform at or near
the level of younger surgeons in measures of memory, visual learning,
reaction time, and attention. This was so even among retired surgeons and
amongst almost 75% senior surgeons planning to retire within 5 years. The
data suggest objective measures of cognitive functionmay be useful in aiding
senior surgeons in their decision to retire. Given the anticipated shortfall of
practicing surgeons in the work force, retention of senior surgeons with
intact cognitive function may be one of many factors important in providing
adequate health care services to the population in the near and intermediate
future.
Endovascular Repair of Descending Thoracic Aneurysms: Results with
“On-Label” Application in the Post Food and Drug Administration
Approval Era
Hughes GC, Lee SM, Daneshmand MA, et al. Ann Thorac Surg 2010;90:
83-9.
Conclusion: Patients treated with thoracic endovascular aneurysm
repair (TEVAR) for “on-label” indications for descending thoracic aortic
aneurysms have excellent 30-day and midterm outcomes.
Summary: In March 2005, the Food and Drug Administration (FDA)
approved the first endovascular device designed for treatment of descending
thoracic aortic aneurysms. Approval was based on highly selected trials of
patients with descending thoracic aneurysms (Makaroun MS et al, J Vasc
Surg 2005;41:1-9; and Bavaria JE, J Thorac Cardiovasc Surg 2007;133:
369-77). Since the publication of the pivotal trials, most series of TEVAR
have included a mixture of indications, including dissection, trauma, and
various hybrid approaches; all “off-label” indications. The point of this
article is to provide data on results of TEVAR when the device is used for
an FDA-approved application (repair of descending thoracic aneurysm).
The authors performed, between March 23, 2005 (date of initial FDA
approval) and April 6, 2009, 210 TEVAR procedures. Of these, 79 (38%)
were for saccular (n  31) or fusiform (n  48) descending thoracic aortic
aneurysms. These “on-label” indications are the basis of their report. All
patients receiving hybrid procedures, except for carotid subclavian bypass,
were excluded. Eighty-five percent of devices used were the Gore TAG
1726device (n  67), whereas 10 Zenith TX2s and 5 Talent grafts were im-
planted. In three patients, a mixture of devices were implanted. Median
patient age was 73 4 years, and 56% were men. Mean aortic diameter was
5.8 1.8 cm. Procedures in 24 patients (30%) were considered emergent or
urgent. The 30-day in hospital mortality was 5.1% (1.9% for elective proce-
dures). The 30-day permanent paraplegia rate was 2.5% overall and 1.3% for
elective procedures. There were two late aortic deaths, one from graft
infection and one from aneurysm rupture at a mean follow up of 23  17
months. At 55 months, actuarial midterm survival was 73% with an aortic-
specific survival of 86%. After 30 days, five patients required a secondary
endovascular procedure for type I (n  4) or type II (n  1) endoleaks.
Comment: This is the largest, post-FDA approval, report of TEVAR
for “on-label” application. The results compare favorably with the pivotal
trials. In the commentary accompanying this article, Dr Coselli points out
that the results are similar to open results with descending thoracic aortic
aneurysm in his series. However, in most surgeons’ hands, TEVAR is likely
to produce better results in the older patient with degenerative thoracic
aneurysm than open surgery and should be considered the preferred tech-
nique. TEVAR, when used in compliance with the manufacturer’s instruc-
tions for use, is effective treatment for “on-label” descending thoracic aortic
aneurysm. The results provide validation of the FDA approval process.
Radiologic Importance of High-Resistive Vertebral Artery Doppler
Waveform on Carotid Duplex Ultrasonography
Kim ES, Thompson M, Nacion KM, et al. J Ultrasound Med 2010;29:
1161-5.
Conclusion: A high resistive vertebral artery waveform is associated
with major vertebrobasilar disease in 46% of cases.
Summary: During the performance of duplex ultrasound imaging for
carotid artery disease, the vertebral arteries are usually also routinely exam-
ined. In most centers, however, examination of the vertebral arteries is
limited and generally confined to determining the direction of blood flow in
the vertebral artery. However, it is also possible to obtain qualitative analysis
of Doppler spectral waveform characteristics. A normal vertebral artery has
flow throughout diastole as it feeds the low-resistance circulatory bed of the
brain. A loss of diastolic flow theoretically indicates advanced occlusive distal
vertebrobasilar disease through the creation of increased resistance to circu-
lation. The authors sought to determine associations with high-resistance
pulse Doppler vertebral artery waveforms visualized on color duplex ultra-
sound imaging. They queried their noninvasive vascular laboratory database
for color duplex ultrasound images where a high-resistance vertebral artery
Doppler signal was noted. Patients with unilateral or bilateral high-resistance
vertebral artery waveforms with antegrade vertebral artery flow and who had
correlative other neuroimaging studies 60 days were examined in detail.
Patients were analyzed for the presence of distal vertebral artery stenosis,
basilar artery stenosis or occlusion, dissection, or a congenitally diminutive
vertebral artery, or other abnormalities.
They found 1338 studies with one or more high-resistance vertebral
artery waveforms, of which 79 studies (157 arteries) met the above inclusion
criteria and had adequate correlative neuroimaging. There were 90 high-
resistance waveforms. High-resistance waveforms were equally distributed
between right and left sides. Mean peak systolic velocities of high-resistance
vs low-resistance waveforms were 51.7 vs 63.6 cm/s (P .04). Patients with
high-resistant waveforms had a mean end-diastolic velocity of 4.6 cm/s vs
19.3 cm/s in patients with low-resistance waveforms (P  .001). On
correlative neuroimaging studies, 19% of high-resistant vertebral arteries
were normal, 39% had distal vertebrobasilar stenosis or occlusion, and about
36% were congenitally diminutive. Other abnormalities, such as proximal
stenosis, tortuosity, fibromuscular dysplasia, and basilar artery hyperplasia,
were identified in approximately 7% of patients.
Comment: This is the largest correlative study of neuroimaging with
Doppler waveform of the V2 segment of the vertebral artery. The high
false-positive rate of 18.9% may relate to lack of a single-standard neuroim-
aging comparator or because the vertebral artery waveforms were only
qualitatively assessed as high or low resistance. However, when others
compared vertebral arteries with an end-diastolic velocity of 0 with those
with an end-diastolic velocity0, but still considered high resistance, those
with end-diastolic velocities of 0 were no more likely to have significant
vertebral artery disease on neuroimaging then those with higher end-
diastolic velocities The article is valuable in that it provides insight of the
distribution of abnormalities producing high-resistance vertebral artery
waveforms.
